Overview
Drug-induced enzyme deficiency anemia arises from genetic polymorphisms affecting drug-metabolizing enzymes (DMEs), leading to altered drug metabolism and potential hematologic complications such as anemia 1.Diagnosis
Identification of specific DME genetic polymorphisms (e.g., CYP2D6, CYP2C9, CYP2C19) through genotyping or phenotyping 1.
Laboratory tests including complete blood count (CBC) to assess anemia parameters 1.
Correlation of drug exposure with enzyme activity levels to confirm causality 1.Management
Adjust drug dosing based on individual enzyme activity profiles to mitigate adverse effects 1.
Consider alternative drugs with less reliance on affected DMEs when possible 1.
Regular monitoring of hematologic parameters in patients with identified enzyme deficiencies 1.Special Populations
Pregnancy: Limited evidence; individualized assessment and monitoring recommended due to altered enzyme activity 1.
Pediatrics: Developmental differences in enzyme activity necessitate careful dosing adjustments and close monitoring 1.
Elderly: Increased susceptibility to drug interactions; tailored pharmacotherapy guided by genetic testing advised 1.
Comorbidities: Consideration of multiple medications; genetic profiling can aid in optimizing therapeutic regimens 1.Key Recommendations
Utilize genotyping or phenotyping of genetically polymorphic DMEs to guide dosing and minimize adverse effects in patients receiving relevant medications (Evidence: Moderate) 1.
Regularly monitor hematologic parameters in patients identified with enzyme deficiencies to detect early signs of anemia (Evidence: Moderate) 1.
Individualize drug therapy based on genetic metabolic capacity to improve the risk-benefit ratio, particularly in high-risk populations (Evidence: Expert opinion) 1.References
1 Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. The pharmacogenomics journal 2008. link